Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?
Haas
David W
DW
Department of Medicine, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. david.w.haas@vanderbilt.edu
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D015203:Reproducibility of Results; D018894:Reverse Transcriptase Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors